aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
AssigneeLa Jolla Pharmaceutical Company
InventorsEdward Jess Victoria, David Matthew Marquis, David S. Jones, Lin Yu
Life of this patent
Estimating the term…
Abstract
aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.
Claims25
A composition for inducing specific B cell tolerance to an antiphospholipid (aPL) immunogen associated with an aPL antibody-mediated pathology comprising a conjugate of a nonimmunogenic valency platform molecule and an aPL antibody-binding analog of the immunogen that (a) is a peptide;
- (b) binds specifically to B cells to which the aPL immunogen binds and (c) lacks the T cell epitope(s) of the immunogen.
A method of treating an individual suffering from an antiphospholipid antibody-mediated disease comprising administering an effective amount of a composition comprising
- conjugated to a nonimmunogenic valency platform molecule to the individual.
Dependencies are inferred from the claim text.